Preclinical trials showed a 70% reduction in tumor size and a 10-to-11-day delay in tumor progression, offering a highly adaptable “Lego-brick” framework for future pediatric cancer immunotherapies.
0%
Preclinical trials showed a 70% reduction in tumor size and a 10-to-11-day delay in tumor progression, offering a highly adaptable “Lego-brick” framework for future pediatric cancer immunotherapies.
